2. Bullock J., Rizvi S., Saleh A.M. et al. Rheumatoid arthritis: A brief overview of the treatment. Med Princ Pract. 2018; 27(6): 501–7. https://dx.doi.org/10.1159/000493390.

3. Chopra A., Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol. 2008; 22(4): 583–604. https://dx.doi.org/10.1016/j.berh.2008.07.001.

4. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008; 4: 4–13.

5. Клинические рекомендации. Ревматоидный артрит (утв. Минздравом России). Ассоциация ревматологов России. 2018. ID: КР 250. Доступ: https://legalacts.ru/doc/klinicheskie-rekomendatsii-revmatoidnyi-artrit-utv-minzdravom-rossii (дата обращения – 02.04.2021). [Clinical guidelines. Rheumatoid arthritis (approved by Ministry of Healthcare of Russia). Association of Rheumatologists of Russia. ID: KP 250. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-revmatoidnyi-artrit-utv-minzdravom-rossii (date of access – 02.04.2021).

6. Lin T.C., Yoshida K., Tedeschi S.K. et al. Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2018; 70(5): 724–31. https://dx.doi.org/10.1002/acr.23346.

7. Sztajnbok F., Boechat N.L., Oliveira S.K. et al. Latent tuberculosis infection in patients with juvenile idiopathic arthritis undergoing methotrexate therapy: A longitudinal study with TST and ELISPOT. Pediatr Rheumatol Online J. 2014; 12: 17. https://dx.doi.org/10.1186/1546-0096-12-17.

8. Grove M.L., Hassell A.B., Hay E.M., Shadforth M.F. Adverse reactions to disease modifying anti-rheumatic drugs in clinical practice. QJM. 2001; 94(6): 309–19. https://dx.doi.org/10.1093/qjmed/94.6.309.

9. Thomas K., Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020; 31(Suppl 1): 129–36. https://dx.doi.org/10.31138/mjr.31.1.129.

10. Rasha H.B., Reham A.D., Eman M.E. et al. Elevated cytomegalovirus and Epstein–Barr virus burden in rheumatoid arthritis: A true pathogenic role or just a coincidence. The Egyptian Rheumatologist. 2019; 41(4): 255–59. https://dx.doi.org/10.1016/j.ejr.2019.03.003.

11. Febres-Aldana A.J., Febres-Aldana C.A., Dvir K. et al. Reactivation of Epstein–Barr virus presenting as massive splenomegaly after initiation of golimumab treatment. Case Rep Hematol. 2020; 2020: 3641813. https://dx.doi.org/10.1155/2020/3641813.

12. McKeown E., Pope J.E., Leaf S. Epstein–Barr virus (EBV) prevalence and the risk of reactivation in patients with inflammatory arthritis using anti-TNF agents and in those who are biologic naive. Open Rheumatol J. 2009; 3: 30–34. https://dx.doi.org/10.2174/1874312900903010030.

13. Komura T., Ohta H., Nakai R. et al. Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL‑6 receptor antibody, tocilizumab. Intern Med. 2016; 55(14): 1923–27. https://dx.doi.org/10.2169/internalmedicine.55.5981.

14. Van Duin D., Miranda C., Husni E. Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. Emerg Infect Dis. 2011; 17(4): 754–56. https://dx.doi.org/10.3201/eid1706.101057.

15. Georg H., Burkhard J. M., Yvonne J. et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis. 2004; 39(9): e88–94. https://dx.doi.org/10.1086/425123.

16. Gardine B.J., Haas E.M., Bailey R.C. et al. Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case–control study. Rheumatol Int. 2019; 39(7): 1229–40. https://dx.doi.org/10.1007/s00296-019-04324-6.

17. Государственный реестр лекарственных средств. В 2 т. М.: Медицинский совет. 2009; с. 568.

18. Miceli-Richard C., Gestermann N., Amiel C. et al. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther. 2009; 11(3): R77. https://dx.doi.org/10.1186/ar2708.